Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health.
Romina LevitNaima G Cortes-PerezAlejandra de Moreno de LeblancJade LoiseauAnne AucouturierPhilippe LangellaJean Guy LeBlancLuis G Bermúdez-HumaránPublished in: Gut microbes (2022)
There is now strong evidence to support the interest in using lactic acid bacteria (LAB)in particular, strains of lactococci and lactobacilli, as well as bifidobacteria, for the development of new live vectors for human and animal health purposes. LAB are Gram-positive bacteria that have been used for millennia in the production of fermented foods. In addition, numerous studies have shown that genetically modified LAB and bifodobacteria can induce a systemic and mucosal immune response against certain antigens when administered mucosally. They are therefore good candidates for the development of new mucosal delivery strategies and are attractive alternatives to vaccines based on attenuated pathogenic bacteria whose use presents health risks. This article reviews the most recent research and advances in the use of LAB and bifidobacteria as live delivery vectors for human and animal health.
Keyphrases
- lactic acid
- endothelial cells
- healthcare
- public health
- immune response
- induced pluripotent stem cells
- pluripotent stem cells
- health information
- escherichia coli
- dendritic cells
- randomized controlled trial
- health promotion
- inflammatory response
- human health
- toll like receptor
- systematic review
- ulcerative colitis
- drug induced